Next Article in Journal
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
Next Article in Special Issue
Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006–2019
Previous Article in Journal
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer
Previous Article in Special Issue
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 7
10.3390/cancers13071557
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Erratum to Cancers 2020, 12(12), 3740.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Erratum

Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740

by
Nadia Hindi
1,2,
Irene Carrasco García
1,2,
Alberto Sánchez-Camacho
1,
Antonio Gutierrez
3,
Javier Peinado
4,5,6,
Inmaculada Rincón
4,
Johanna Benedetti
1,
Pilar Sancho
1,
Paloma Santos
1,2,
Paloma Sánchez-Bustos
2,
David Marcilla
7,
Victor Encinas
8,
Sara Chacon
9,
Cristobal Muñoz-Casares
10,
David Moura
2 and
Javier Martin-Broto
1,2,*
1
Medical Oncology Department, Hospital Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013 Sevilla, Spain
2
TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla, HUVR, CSIC, US), 41013 Sevilla, Spain
3
Hematology Department, University Hospital Son Espases, 07120 Mallorca, Spain
4
Radiation Oncology Department, University Hospital Virgen del Rocio, 41013 Sevilla, Spain
5
Biología Molecular del Cáncer, IBiS (Instituto de Biomedicina de Sevilla), 41013 Sevilla, Spain
6
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
7
Pathology Department, Hospital Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013 Sevilla, Spain
8
Musculoskeletal Unit, Radiology Department, Hospital Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013 Sevilla, Spain
9
Musculoskeletal Tumor Unit, Orthopedics Surgery Department, Hospital Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013 Sevilla, Spain
10
Surgery Department, Hospital Universitario Virgen del Rocio, Av Manuel Siurot s/n, 41013 Sevilla, Spain
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(7), 1557; https://doi.org/10.3390/cancers13071557
Submission received: 19 February 2021 / Accepted: 22 February 2021 / Published: 29 March 2021
(This article belongs to the Special Issue New Therapeutic Advances in Rare Tumors)
Versions Notes
The authors noticed that content of “Conflicts of Interest” in the original version [1] was missing and would like to make a correction:
It should be changed from “Conflicts of Interest: The authors declare no conflict of interest.” to “Conflicts of Interest: Nadia Hindi reports grants, personal fees and non-financial support from PharmaMar, personal fees from Eli Lilly, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, Bristol Myers Squibb, Pfizer and Daichii-Sankyo. Irene Carrasco García, Alberto Sánchez-Camacho, Johanna Benedetti, Pilar Sancho, and Paloma Santos declare research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, and Daichii–Sankyo. Paloma Sanchez-Bustos and David S. Moura report institutional research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer, and Pfizer. Javier Martin-Broto reports research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly, and Company, Bayer, and Eisai; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly, and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, Bristol Myers Squibb, Pfizer, and Daichii-Sankyo. All the other authors report no conflicts of interest.”
We apologize for this error and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. Hindi, N.; Carrasco García, I.; Sánchez-Camacho, A.; Gutierrez, A.; Peinado, J.; Rincón, I.; Benedetti, J.; Sancho, P.; Santos, P.; Sánchez-Bustos, P.; et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hindi, N.; García, I.C.; Sánchez-Camacho, A.; Gutierrez, A.; Peinado, J.; Rincón, I.; Benedetti, J.; Sancho, P.; Santos, P.; Sánchez-Bustos, P.; et al. Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740. Cancers 2021, 13, 1557. https://doi.org/10.3390/cancers13071557

AMA Style

Hindi N, García IC, Sánchez-Camacho A, Gutierrez A, Peinado J, Rincón I, Benedetti J, Sancho P, Santos P, Sánchez-Bustos P, et al. Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740. Cancers. 2021; 13(7):1557. https://doi.org/10.3390/cancers13071557

Chicago/Turabian Style

Hindi, Nadia, Irene Carrasco García, Alberto Sánchez-Camacho, Antonio Gutierrez, Javier Peinado, Inmaculada Rincón, Johanna Benedetti, Pilar Sancho, Paloma Santos, Paloma Sánchez-Bustos, and et al. 2021. "Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740" Cancers 13, no. 7: 1557. https://doi.org/10.3390/cancers13071557

APA Style

Hindi, N., García, I. C., Sánchez-Camacho, A., Gutierrez, A., Peinado, J., Rincón, I., Benedetti, J., Sancho, P., Santos, P., Sánchez-Bustos, P., Marcilla, D., Encinas, V., Chacon, S., Muñoz-Casares, C., Moura, D., & Martin-Broto, J. (2021). Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740. Cancers, 13(7), 1557. https://doi.org/10.3390/cancers13071557

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop